Track topics on Twitter Track topics that are important to you
A novel treatment option for some patients with rheumatoid arthritis (RA) could soon be routinely available on the NHS, after cost regulators ruled Eli Lilly’s Olumiant to be cost-effective with the inclusion of a confidential patient access scheme.
Original Article: NICE backs Lilly’s JAK inhibitor Olumiant for RANEXT ARTICLE
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...